Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 6/20 | 0.41 |
| ▸ | ADORA2A | P29274 | 6/20 | 0.41 |
| ▸ | RAB9A | P51151 | 2/20 | 0.40 |
| ▸ | ADORA1 | P30542 | 6/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | NR2F2 | P24468 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 3/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | ADORA2B | P29275 | 4/20 | 0.36 |
| ▸ | PDE5A | O76074 | 2/20 | 0.36 |
| ▸ | ACP1 | P24666 | 2/20 | 0.36 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.36 |
| ▸ | PDE7A | Q13946 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | FYN | P06241 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5450469 | 0.79 | RAB9A (0.40) | ADORA3ADORA2ARAB9AADORA1MEN1 | |
| SCHEMBL5458250 | 0.76 | RAB9A (0.57) | ADORA3ADORA2ARAB9AADORA1MEN1 | |
| SCHEMBL5455719 | 0.72 | MAPK13 (0.40) | ADORA3ADORA2ARAB9AADORA1KMT2A | |
| SCHEMBL5453146 | 0.67 | ADORA3 (0.44) | ADORA3ADORA2ARAB9AADORA1NPC1 | |
| SCHEMBL5458126 | 0.63 | MAPK10 (0.52) | ADORA3ADORA2AADORA1ADORA2B | |
| SCHEMBL1487735 | 0.62 | CDK9 (0.43) | — | |
| SCHEMBL556037 | 0.62 | KMT2A (0.52) | ADORA2ARAB9AMEN1NPC1KMT2A | |
| SCHEMBL1486116 | 0.61 | CSNK2B (0.50) | ADORA1MEN1KMT2APDE7A | |
| SCHEMBL19742491 | 0.61 | CSNK2A1 (0.50) | — | |
| SCHEMBL21379988 | 0.60 | NPSR1 (0.54) | ADORA2ARAB9AADORA1NPC1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070232623-A1 | Pyrazolopyrimidine and Pyrazolotriazine Derivatives and Pharmaceutical Compositions Containing Them | GUDMUNDSSON KRISTJAN | 2007-10-04 | — | — | US | disclosed |
| US-7247626-B2 | Pyrazolopyrimidine derivatives and pharmaceutical compositions containing them | SMITHKLINE BEECHAM CORPORATION (US) | 2007-07-24 | — | — | US | disclosed |
| EP-1485385-B1 | PYRAZOLOPYRIMIDINE AND PYRAZOLOTRIAZINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | SMITHKLINE BEECHAM CORP (US) | 2005-08-17 | — | — | EP | disclosed |
| US-20050124616-A1 | Pyrazolopyrimidine and pyrazolotriazine derivatives and pharmaceutical compositions containing them | SMITHKLINE BEECHAM CORPORATION | 2005-06-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050124616-A1 | Pyrazolopyrimidine and pyrazolotriazine derivatives and pharmaceutical compositions containing them | CYP3A5, CYP3A4, CYP3A7 | ADORA3 1419/4885ADORA2A 1145/4885RAB9A 3001/4885 |
| US-20070232623-A1 | Pyrazolopyrimidine and Pyrazolotriazine Derivatives and Pharmaceutical Compositions Containing Them | CYP3A5, CYP3A4, CYP3A7 | ADORA3 1419/4885ADORA2A 1145/4885RAB9A 3001/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.